State Street Corp Has $1.76 Million Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

State Street Corp cut its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 216,021 shares of the company’s stock after selling 9,876,644 shares during the quarter. State Street Corp’s holdings in Ginkgo Bioworks were worth $1,761,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of DNA. AQR Capital Management LLC bought a new position in Ginkgo Bioworks during the 2nd quarter worth about $3,391,000. Monaco Asset Management SAM bought a new position in Ginkgo Bioworks during the second quarter worth about $3,276,000. Renaissance Technologies LLC bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at $2,128,000. XTX Topco Ltd acquired a new position in Ginkgo Bioworks in the 2nd quarter valued at about $312,000. Finally, Mackenzie Financial Corp acquired a new stake in Ginkgo Bioworks during the second quarter worth approximately $251,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Stock Up 4.0 %

Shares of NYSE:DNA opened at $9.82 on Thursday. The firm has a 50 day moving average price of $8.74. The firm has a market cap of $564.44 million, a PE ratio of -0.75 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $68.80.

Analyst Ratings Changes

Separately, TD Cowen increased their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.